A BILL 
To amend the Federal Food, Drug, and Cosmetic Act regard-
ing the list under section 505(j)(7) of the Federal Food, 
Drug, and Cosmetic Act, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Orange Book Trans-
4
parency Act of 2019’’. 
5
SEC. 2. ORANGE BOOK. 
6
(a) PATENTS.—Clause (iii) of section 505(j)(7)(A) of 
7
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
8
355(j)(7)) is amended to read as follows: 
9
00:08 Mar 16, 2019
H1503
2 
•HR 1503 IH
‘‘(iii)(I) When patent information submitted under 
1
subsection (b) or (c) respecting a drug included on the 
2
list is to be published by the Secretary, the Secretary shall, 
3
in revisions made under clause (ii), include such informa-
4
tion for such drug. 
5
‘‘(II) The Secretary— 
6
‘‘(aa) shall include on the list, from such patent 
7
information respecting a drug, drug substance (in-
8
cluding active ingredient) patents, drug product (in-
9
cluding formulation and composition) patents, and 
10
method of use patents; and 
11
‘‘(bb) may choose to include on the list addi-
12
tional patent information respecting the drug. 
13
‘‘(III) The Secretary shall not include on the list any 
14
patent to the extent such patent claims a device that is 
15
used for the delivery of the drug. Notwithstanding the pre-
16
ceding sentence, the Secretary may require (under other 
17
applicable provisions of law) the holder of the approved 
18
application for a drug to submit, for purposes other than 
19
the list under this paragraph, patent information respect-
20
ing a device that is used for the delivery of the drug.’’. 
21
(b) LISTING OF EXCLUSIVITIES.—Subparagraph (A) 
22
of section 505(j)(7) of the Federal Food, Drug, and Cos-
23
metic Act (21 U.S.C. 355(j)(7)) is amended by adding at 
24
the end the following: 
25
00:08 Mar 16, 2019
H1503
3 
•HR 1503 IH
‘‘(iv) For each drug included on the list, the Sec-
1
retary shall specify each exclusivity period that is applica-
2
ble and has not concluded under— 
3
‘‘(I) clause (iii) or (iv) of subsection (c)(3)(E) 
4
of this section; 
5
‘‘(II) clause (iv) or (v) of paragraph (5)(B) of 
6
this subsection; 
7
‘‘(III) clause (iii) or (iv) of paragraph (5)(F) of 
8
this subsection; 
9
‘‘(IV) section 505A; 
10
‘‘(V) section 505E; or 
11
‘‘(VI) section 527(a).’’. 
12
(c) REMOVAL OF INVALID PATENTS.— 
13
(1) IN
GENERAL.—Section 505(j)(7) of the 
14
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
15
355(j)(7)) is amended by adding at the end the fol-
16
lowing: 
17
‘‘(D)(i) The holder of an application approved under 
18
subsection (c) for a drug on the list shall promptly notify 
19
the Secretary in writing if either of the following occurs: 
20
‘‘(I) The Patent Trial and Appeals Board issues 
21
a decision that a patent for such drug is invalid. 
22
‘‘(II) A court issues a decision from which no 
23
appeal may be taken that a patent for such drug is 
24
invalid. 
25
00:08 Mar 16, 2019
H1503
4 
•HR 1503 IH
‘‘(ii) The holder of an approved application shall in-
1
clude in any notification under clause (i) a copy of the 
2
decision described in subclause (I) or (II) of clause (i). 
3
‘‘(iii) The Secretary shall remove from the list any 
4
patent that is determined to be invalid in a decision de-
5
scribed in subclause (I) or (II) of clause (i)— 
6
‘‘(I) promptly; but 
7
‘‘(II) not before the expiration of any 180-day 
8
exclusivity period under clause (iv) or (v) of para-
9
graph (5)(B) that relies on a certification described 
10
in paragraph (2)(A)(vii)(IV) that such patent was 
11
invalid.’’. 
12
(2) APPLICABILITY.—Subparagraph (D) of sec-
13
tion 505(j)(7) of the Federal Food, Drug, and Cos-
14
metic Act (21 U.S.C. 355(j)(7)), as added by para-
15
graph (1), applies only with respect to a decision de-
16
scribed in such subparagraph that is issued on or 
17
after the date of enactment of this Act. 
18
(d) REVIEW AND REPORT.—Not later than one year 
19
after the date of enactment of this Act, the Secretary of 
20
Health and Human Services, acting through the Commis-
21
sioner of Food and Drugs, shall— 
22
(1) review the types of patent information that 
23
should be included on the list under section 
24
00:08 Mar 16, 2019
H1503
5 
•HR 1503 IH
507(j)(7) of the Federal Food, Drug, and Cosmetic 
1
Act (21 U.S.C. 355(j)(7)); and 
2
(2) report to the Congress on the results of 
3
such review, including any recommendations about 
4
the types of patent information that should be in-
5
cluded on or removed from such list. 
6
Æ 
00:08 Mar 16, 2019
H1503
